UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2022

Commission File Number 001-38370

CollPlant Biotechnologies Ltd. (Exact name of registrant as specified in its charter)

4 Oppenheimer St, Weizmann Science Park Rehovot 7670104, Israel (Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ⊠ Form 40-F □

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): 🗆

CollPlant Biotechnologies Ltd. has posted to its website an updated corporate presentation. A copy of the presentation is furnished with this Report of Foreign Private Issuer on Form 6-K as Exhibit 99.1 and is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: April 14, 2022

COLLPLANT BIOTECHNOLOGIES LTD.

By: /s/ Eran Rotem

Name:Eran RotemTitle:Deputy CEO and Chief Financial Officer



Safe harbor statement

Certain statements in this presentation constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and meaning or section 27A or the section section 21E or the sections exchange Act and are usually identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," will," and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and are expected to be affected by a variety of risks and factors that are beyond our control. Risks and uncertainties for our company include, but are not limited to: the Company's history of significant losses and its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all: the Company's expectations regarding the timing and cost of commencing clinical trials with respect to tissues and organs which are based on its rhCollagen based Bioink and products for medical aesthetics; the Company's ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen based Biolnkand medical aesthetics products including but not limited to acceptance of an application for marketing authorization, review and approval such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the Company's rhCollagen based products, in 3D bioprinting and medical aesthetics; the Company's ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and resellers; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations; the Company's reliance on third parties to conduct some or all aspects of its product manufacturing; the scope of protection the Company is able to establish and maintain for intellectual property rights and the Company's ability to operate its business without infringing the intellectual property rights of others; the overall global economic environment; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the Company operates; projected

capital expenditures and liquidity; changes in the Company's strategy; and litigation and regulatory proceedings. Many of these factors that will determine actual results are beyond our ability to control or predict. For a discussion of the factors that may cause our actual results, performance or achievements to differ materially from any future results, performance or achievements to differ materially from any future results, performance or achievements to differ materially from any future results, see the "Risk Factors" section of included in our most recently filed Annual Report on Form 20-F. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

The statements made in this presentation speak only as of the date stated herein, and subsequent events and developments may cause our expectations and beliefs to change. Unless otherwise required by applicable securities laws, we do not intend, nor do we undertake any obligation, to update or revise any forward-looking statements contained in this presentation to reflect subsequent information, events, results or circumstances or otherwise. While we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, whether as a result of new information, future events or otherwise, except as required by law.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of such products.

CollPlant

CollPlant – Unlocking the Regenerative Potential of rhCollagen



Regenerative and Aesthetic Medicine Company

Developing innovative technologies and products for tissue regeneration and organ manufacturing, to help people live longer and better



Proprietary Plant-based Technology Platform

Only commercially viable solution for mass production of rhCollagen



Collaboration Agreements with Industry Leaders

- AbbVie (ABBV)- Worldwide exclusive agreement for dermal and soft tissue fillers. Up to \$103mm in payments plus royalties.
- 3D Systems (DDD)-Bioprinted solutions for breast reconstruction treatments



Well Capitalized

\$43mm in cash

Zero deb

(December 31, 2021)

(CollPlant



Plant-based platform produces human collagen in mass-scale

Expressing 5 human genes





Product Pipeline





Dermal fillers market overview



Collaboration agreement with AbbVie



Financial highlights:



- Up to \$103M in potential payments, including:
- \$14M upfront payment
- Up to \$89M milestones and option payments



Royalties on products sales



CollPlant will manufacture and sell to AbbVie the rhCollagen used in the products



rhCollagen-based photocurable regenerative dermal filler* key attributes



3D Bioprinted Tissues and Organs



3D bioprinting represents a wide range of development opportunities



Breast Reconstruction / Augmentation

Breast implants market overview





- * Study on large animals will be initiated in Q2 2022
- ** ECM- extracellular matrix



Regenerative Tissue Matrix (RTM) Developed in collaboration with 3D Systems



Injectable breast implants*

- Composed of rhCollagen and additional materials, intended to promote breast tissue regeneration
- Designed to attract cells to promote tissue regeneration and support the viability and function of the newly regenerated tissue
- The scaffold is designed to gradually degrade and be replaced by newly grown natural breast tissue that is free of any foreign material

CollPlant

* AbbVie's Option Product

rhCollagen Biolnk compositions in development



CollinK-3D>

CollPlant now offers Collink.3D[™], human collagen bioink platform, for 3D bioprinting of organs, scaffolds and tissue models for drug discovery, personalized medicine and regenerative medicine applications.

Contraction of the second seco

Collink(3D)

Our Partners

Companies

Supply agreement



Collaboration agreement



Development and commercialization agreement



Joint development agreement

Consortiums & organizations



Scalable manufacturing of tissue engineered products



Universal Biolnk



Industry committee

Experienced management team



Yehiel Tal CEO Regentis Biomaterials ProChon Biotech Kulicke & Soffa Industries



Eran Rotem Deputy CEO & CFO Tefron, CFO (NYSE,TASE) Healthcare Tech., CFO (NASDAQ) & Gamida E&Y



Michal Roytman VP Sales & Marketing Ocon Medical

Ocon Medical Neuroderm (now Mitsubishi Tanabe) Neurim Pharmaceuticals Frutarom (now IFF)



21

Ilana Belzer, PhD COO BioHarvest Procognia Ltd. Omrix Biopharmaceuticals Interpharm



Philippe Bensimon, PharmD VP RA/QA/CA Maquet Getinge 3M Medical







CollPlant investment thesis



Only commercially viable technology currently available that can produce truly human collagen

Multi-billion dollar markets: innovative rhCollagen products initially aimed at 3D bioprinting and medical aesthetics

Broadly applicable technology: Ideal building block/scaffolding molecule for regenerative medicine



Clinically validated technology

Proven management team



